
Nkarta, Inc. (NKTX) Stock Forecast & Price Target
Nkarta, Inc. (NKTX) Analyst Ratings
Bulls say
Nkarta Inc. is positioned favorably in the biopharmaceutical sector due to its innovative approach towards developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for cancer treatment. The company's decision to reincorporate standardized lymphodepletion with fludarabine has significantly enhanced patient enrollment, indicating a strong operational momentum. Moreover, Nkarta's potential to capitalize on the biological and logistical advantages of NK cell therapies over traditional CAR-T therapies further supports a positive outlook from investors seeking exposure in this emerging therapeutic category.
Bears say
Nkarta Inc's financial outlook is negatively impacted by a significant decrease in research and development (R&D) spending, which was reported at $21 million, down 14% sequentially, raising concerns about the company’s ability to effectively fund its clinical programs. Additionally, the company's decision to amend its NKX019 treatment protocol and postpone preliminary year-end 2025 data disclosure has created uncertainty regarding the efficacy of its therapies, as management anticipates presenting more comprehensive results only at a FY26 medical conference. This delay, coupled with a substantial drop in selling, general, and administrative (SG&A) expenses, which fell 48% sequentially, suggests potential operational challenges and raises questions about the stability of Nkarta's growth trajectory in an increasingly competitive biopharmaceutical landscape.
This aggregate rating is based on analysts' research of Nkarta, Inc. and is not a guaranteed prediction by Public.com or investment advice.
Nkarta, Inc. (NKTX) Analyst Forecast & Price Prediction
Start investing in Nkarta, Inc. (NKTX)
Order type
Buy in
Order amount
Est. shares
0 shares